The alexipharmic drugs global market report 2024from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.
Alexipharmic Drugs Market, 2024report by The Business Research Company offers
comprehensive insights into the current state of the market and highlights
future growth opportunities.
Market Size - The alexipharmic drugs market size has grown strongly in recent
years. It will grow from $2.90 billion in 2023 to $3.05 billion in 2024 at a
compound annual growth rate (CAGR) of 5.4%. The growth in the historic period
can be attributed to the increased prevalence of poisoning cases worldwide,
regulatory approvals for new antidote formulations, rise in awareness about the
importance of poison management, improvements in emergency medical services and
poison control centers, and development of novel antidote delivery systems.
The alexipharmic drugs market size is expected to see strong growth in the next
few years. It will grow to $3.80 billion in 2028 at a compound annual growth
rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to
increasing incidence of drug overdoses and substance abuse, expanding
applications of antidotes in various medical specialties, rising demand for
fast-acting and potent antidote formulations, growing adoption of antidote kits
in home healthcare settings, healthcare reforms emphasizing poison prevention
and management initiatives. Major trends in the forecast period include
personalized antidote therapies tailored to individual patient needs,
integration of digital health technologies in poison management solutions,
increasing use of nanotechnology in antidote formulation and delivery, emphasis
on eco-friendly and sustainable antidote manufacturing practices, and expansion
of telemedicine services for poison consultation and management.
Order your report now for swift delivery @ https://www.thebusinessresearchcompany.com/report/alexipharmic-drugs-global-market-report
Scope Of Alexipharmic Drugs MarketThe Business Research Company's reports
encompass a wide range of information, including:
1. Market Size (Historic and Forecast): Analysis of the market's historical
performance and projections for future growth.
2. Drivers: Examination of the key factors propelling market growth.
3. Trends: Identification of emerging trends and patterns shaping the market
landscape.
4. Key Segments: Breakdown of the market into its primary segments and their
respective performance.
5. Focus Regions and Geographies: Insight into the most critical regions and
geographical areas influencing the market.
6. Macro Economic Factors: Assessment of broader economic elements impacting
the market.
Alexipharmic Drugs Market Overview
Market Drivers -The rise in the death rate due to drug overdose is expected to
propel the growth of the alexipharmic drugs market going forward. Drug overdose
refers to the consumption of a substance beyond the body's tolerance level,
often resulting in adverse effects or death. Drug overdose death includes
accessibility to potent substances, socioeconomic disparities, mental health
issues, and inadequate access to addiction treatment and harm reduction
services. Alexipharmic drugs play a crucial role in minimizing the death rate
by counteracting the toxic effects of drugs in cases of overdose, thereby
preventing or reducing fatalities. For instance, in December 2023, according to
the Office for National Statistics, the UK-based executive office of the UK
Statistics Authority, in England and Wales, there were 4,907 drug poisoning
deaths in 2022 compared to 4,859 in 2021, with nearly half involving opiates
(46.1%; 2,261 deaths), while cocaine-related deaths rose by 2.0% to 857,
marking a consecutive annual increase. Therefore, the rise in the death rate
due to drug overdose is driving the alexipharmic drugs market.
Market Trends - Major companies operating in the alexipharmic drugs market are
increasing their focus on developing advanced solutions, such as the first over-the-counter
(OTC) opioid overdose reversal medication, to gain a competitive edge in the
market. The first over-the-counter (OTC) opioid overdose reversal medication
refers to a medication available without a prescription that can counteract the
effects of opioid overdose, providing life-saving treatment in emergencies. For
instance, in August 2023, Emergent BioSolutions, a US-based biopharmaceutical
company, announced that NARCAN Naloxone HCl Nasal Spray 4 mg will be available
over-the-counter (OTC). This includes its same safe and effective 4 mg
formulation, device design, and original prescription strength, offering
convenient and easy two-step intranasal administration to reverse opioid
effects, including fentanyl. This solution significantly expands access to
naloxone, reducing stigma and encouraging public preparedness, thereby
empowering more individuals to respond effectively in opioid emergencies,
ultimately contributing to saving lives and addressing the opioid crisis in the
alexipharmic drugs market.
The alexipharmic drugs market covered in this report is segmented –
1) By Type: Chemical Antidote, Physical Antidote, Pharmacological Antidote
2) By Route Of Administration: Oral, Topical, Injectable, Other Routes Of
Administration
3) By Application: Opioid Overdose, Alcohol Overdose, Cyanide Poisoning, Lead
Poisoning, Benzodiazepine Overdose, Other Applications
4) By End Use: Hospital, Homecare, Specialty Clinics, Other End Uses
Get an inside scoop of the alexipharmic drugs market, Request now for Sample
Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=15507&type=smp
Regional Insights - North America was the largest region in the alexipharmic
drugs market in 2023. Asia-Pacific is expected to be the fastest-growing region
in the forecast period. The regions covered in the alexipharmic drugs market
report are Asia-Pacific, Western Europe, Eastern Europe, North America, South
America, Middle East, Africa.
Key Companies - Major companies operating in the alexipharmic drugs market are
Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc.,
Sanofi S.A., Bristol Myers Squibb Company (Bristol-Myers Squibb Company),
AstraZeneca, Novartis AG, GlaxoSmithKline plc, Gilead Sciences Inc., Teva
Pharmaceutical Industries Ltd., Fresenius SE & Co. KGaA (Fresenius Kabi),
Bausch Health Companies Inc., UCB S.A., Sun Pharmaceutical Industries Ltd., B.
Braun SE, Aurobindo Pharma, Purdue Pharma L.P., Cipla Inc., Hikma
Pharmaceuticals, Amneal Pharmaceuticals, Vifor Pharma Group, Lupin Limited,
Alkermes Inc., Emergent BioSolutions, Ethypharm S.A., Alpharma Pharmaceuticals
Inc., Accord Healthcare, BTG plc, Gavis Pharmaceuticals, Apotex Inc.
Table of Contents 1. Executive Summary2. Alexipharmic Drugs Market Report
Structure3. Alexipharmic Drugs Market Trends And Strategies4. Alexipharmic
Drugs Market – Macro Economic Scenario5. Alexipharmic Drugs Market Size And
Growth…..27. Alexipharmic Drugs Market Competitor Landscape And Company
Profiles28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model:
https://www.thebusinessresearchcompany.com/global-market-model
No comments:
Post a Comment